1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Chong Kun Dang Holdings Co., Ltd.

Chong Kun Dang Holdings Co., Ltd.

KKRX:001630
35,550.00
KRW
-50.00
(-0.14%)
14,346.45EPS
3.47P/E
186.14BMarket Cap
Nov 18Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
175,555.24
54,069.92
57,092.32
75,617.66
91,688.38
106,020.8
143,842.53
171,360.61
185,968.72
185,268.26
182,366.37
201,181.02
201,457.66
202,002.72
Basic EPS, GAAP
130,186.72
2,820
3,914
6,630
9,766
5,481
8,988
15,711
3,212
219
9,744
7,057
8,493
11,274.81
Free Cash Flow per Basic Share
6,452.06
-3,412.76
-5,373.73
-1,905.15
8,146.61
-2,972.45
-3,707.06
-10,264.17
-12,588
-22,781.76
1,051.02
-94.53
3,865.98
2,737.23
Dividend per Share
3,151.29
2,490.1
1,283.73
2,154.94
2,072.93
2,590.15
1,922.16
2,084.65
2,184.27
2,118.44
2,081.58
2,725.07
2,194.52
1,179.71
Book Value per Share
44,332.23
47,078.02
69,843.89
76,263.22
81,621.7
85,684.9
93,600.12
108,137.9
109,358.48
108,745
118,253.02
123,409.58
133,812.82
137,835.05
Tangible Book Value per Share
43,269.33
45,727.72
68,697.74
70,347.31
76,368.04
80,413.5
88,401.12
102,660.65
104,200.05
102,702.2
112,521.29
116,809.66
124,591.02
128,208.35
Basic Weighted Avg Shares
3
3
4
4
5
5
5
5
5
5
5
5
5
5
Sales/Revenue/Turnover
560,618
181,395
221,832
335,676
450,735
531,114
720,644
858,119
925,975
908,963
879,781
957,753
959,012
961,643
Operating Margin (%)
14.71
16.94
12.7
6.87
9.65
10.09
11.89
10.4
3.72
-3.62
1.93
3.71
6.08
5.85
Depreciation Expense
21,187
7,294
8,766
16,678
24,073
24,145
27,507
30,346
35,736
42,943
45,280
43,338
44,033
45,260
Net Income, GAAP
415,738
9,461
15,208
29,431
48,009
27,457
45,029
78,676
15,993
1,074
47,007
33,596
40,430
53,674
Effective Tax Rate (%)
5.1
63.71
7.32
12.33
14.92
21.63
19.15
21.09
7.45
- -
7.16
0.21
16.62
20.44
Profit Margin (%)
74.16
5.22
6.86
8.77
10.65
5.17
6.25
9.17
1.73
0.12
5.34
3.51
4.22
5.58
Working Capital
67,928
54,776
118,746
161,638
170,009
145,452
96,307
114,004
119,157
-812
-100,229
-63,614
-116,663
-103,721
LT Debt
6,750
10,000
5,000
169
1,564
16,428
48,713
85,168
163,388
141,360
74,438
108,338
58,513
101,854
Total Equity
185,302
188,465
381,241
548,025
640,194
670,779
740,065
840,301
839,968
798,544
823,485
849,773
913,055
933,869
Return on Invested Capital (%)
19.52
4.67
7.58
3.85
5.68
5.87
8.45
7.13
2.82
- -
1.25
2.7
3.49
3.05
Return on Capital (%)
104.4
2.63
0.29
3.32
4.62
0.45
1.6
4.76
0.91
- -
5.69
3.62
3.15
3.69
Return on Common Equity (%)
163.97
6.17
6.75
9.01
12.48
6.55
10.03
15.59
2.96
0.2
8.61
5.84
6.6
8.55

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
482,297
480,087
501,013
LT Borrowings
55,802
84,519
99,138
LT Finance Leases
2,711
2,956
2,716
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
220,176
222,318
186,138

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
499,121
521,908
560,843
Cash, Cash Equivalents & STI
117,101
145,938
154,234
Accounts Receivable, Net
138,828
138,428
154,656
Inventories
224,240
216,729
216,563
Total Current Liabilities
615,784
628,159
664,564
Payables & Accruals
- -
- -
- -
ST Debt
482,297
480,087
501,013
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.8%
1.76%
7.45%
Free Cash Flow
-487.13%
-860.51%
-4,189.42%
Net Income, GAAP
434.64%
818.77%
20.34%
Sales/Revenue/Turnover
17%
2.37%
0.13%
Total Cash Common Dividend
11.43%
1.22%
-19.47%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
249,992
248,442
232,243
227,075
957,753
2025
246,621
242,184
234,219
235,989
959,012
2026
240,267
251,169
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,848
3,216
980
1,013.12
7,057
2025
1,247
2,218
2,815.05
2,212.22
8,493
2026
2,707.55
3,540
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
2,725.07
2025
- -
- -
1,179.71
- -
2,194.52
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hee-Nam Choi
Full Time Employees
38
Sector
Health technology
Industry
Pharmaceuticals: major
Address
8, Chungjeong-ro Seoul SL South Korea
IPO Date
Jun 30, 1976
Website
ckd-holdings.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Chong Kun Dang Holdings Corp. (001630.KS) serves as the holding company for the Chong Kun Dang group, primarily engaged in pharmaceuticals, healthcare, and bio sectors through its subsidiaries. The company oversees the development, manufacturing, and distribution of prescription drugs, over-the-counter medications, and biologics; contract manufacturing services for generics and innovative medicines; and healthcare solutions including diagnostics and medical devices. Its core offerings encompass anti-infectives, cardiovascular treatments, oncology drugs under brands like CKD and Zydus-CKD; nutraceuticals; and bio-similars, targeting hospitals, pharmacies, and global export markets across Asia, Europe, and the Americas. Founded in 1941 and headquartered in Seoul, South Korea, Chong Kun Dang Holdings operates primarily in South Korea with international subsidiaries and partnerships extending to India, Vietnam, and the United States. Recent major developments include the 2023 strategic alliance with Zydus Lifesciences for biosimilar production and market expansion in emerging economies; a KRW 500 billion funding round in 2024 to bolster R&D in cell and gene therapies; and the launch of a new GLP-1 receptor agonist for diabetes management in late 2024. The company acquired a majority stake in a Vietnamese pharmaceutical firm in early 2025 to enhance Southeast Asian operations and announced a reorganization in mid-2025 to streamline its bio division amid rising demand for innovative therapies. These initiatives reflect Chong Kun Dang Holdings' shift toward high-value biologics and global expansion, supported by its affiliates such as Chong Kun Dang Pharmaceutical Corp. and CKD Bio.